Health
New obesity drugs win support of doctors and insurers, which could lift these pharma names even higher
Drugs that treat obesity and overweight are improving their efficacy. They are also increasingly being prescribed by doctors and covered by insurers – a win for patients and for investors. “While supply is still a top concern for Wegovy, we’ve been impressed with commercial formulary access for obesity,” Geoff Meacham, an analyst at Bank of […]
Read More
2 takeaways from our daily meeting: Selling in an overbought market, updates on 3 holdings
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. It’s not too late to sell Quick mentions: QCOM, COST, HUM 1. It’s not too late to sell Stocks fell on Thursday, continuing Wednesday’s losses after the Federal Reserve reaffirmed […]
Read More
Magic mushroom compound psilocybin can help treat depression, study finds
The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type ever conducted. David Buzzard – media-centre.ca / Getty Images LONDON — The naturally occurring psychedelic compound psilocybin can significantly reduce symptoms of depression, according to data from the largest trial of its type […]
Read More
Moderna shares plummet after Covid vaccine maker lowers 2022 sales outlook
A vial of the Moderna coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, September 8, 2022. Hannah Beier | Reuters Moderna on Thursday lowered its 2022 sales guidance for its Covid-19 vaccine after missing Wall Street expectations for the third quarter. The Boston […]
Read More
We’re impressed with health insurer Humana’s solid quarter and rosy outlook for next year
Club holding Humana (HUM) reported a mixed-but-solid third quarter before the opening bell Wednesday. Early optimism about 2023 also supported our bullish view on the health insurer’s stock. Revenue increased 9% year-over-year to $22.75 billion, slightly below estimates of $22.76 billion, and adjusted earnings-per-share increased 42% to $6.88, exceeding estimates of $6.28 per share. Aiding […]
Read More
2 takeaways from our daily meeting: Stocks await Fed decision, Club earnings recap
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Fed decision ahead Quick takes on Club earnings 1. Fed decision ahead Stocks edged down Wednesday ahead of the Federal Reserve’s decision on interest rate increases, set for this afternoon. […]
Read More
Eli Lilly’s guidance cut is about the strong dollar, not weakening fundamentals, CEO says
Eli Lilly (LLY) CEO David Ricks on Tuesday expressed optimism around the drugmaker’s innovation pipeline Tuesday, a stance we share despite the Club holding’s cluttered quarterly report issued earlier in the day . “The underlying fundamentals of the business are really strong,” Ricks said in a CNBC interview with Jim Cramer. “Seventy percent of our […]
Read More
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021. John Thys | AFP | Getty Images Pfizer CEO Albert Bourla laid out his plan Tuesday […]
Read More
Pfizer raises 2022 earnings guidance, beats third-quarter expectations
Vials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022. Rodrigo Garrido | Reuters Pfizer on Tuesday raised its 2022 earnings guidance after booking a strong third quarter that beat Wall Street expectations. Pfizer now expects earnings per share […]
Read More
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company’s data shows
Pfizer’s vaccine against respiratory syncytial virus, or RSV, is highly effective at protecting newborns when the shot is given to the mothers late in their pregnancy, according to clinical trial data published Tuesday. RSV is a common respiratory virus that generally causes mild cold-like symptoms, but it can be dangerous for infants younger than 6 […]
Read More